Bayer will pay $400 million -- and up to $1.15 million more in milestones tied to regulatory approvals and sales -- for commercial rights to a rare cancer drug being developed by Loxo Oncology, a small Stamford, Conn.-based biotechnology firm.
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2017/11/14/bayer-commits-1-55-billion-to-get-loxos-rare-cancer-drug/
via IFTTT
No comments:
Post a Comment